Lucid Diagnostics Prices $18 Million Direct Offering of Common Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy PAVM?
Source: PRnewswire
- Offering Size: Lucid Diagnostics announced the pricing of 18 million common shares at $1.00 each, expecting gross proceeds of approximately $18 million, which will provide essential funding for working capital and general corporate purposes.
- Investor Backing: The offering is anchored by a $15 million investment from a fundamental institutional investor, along with support from a large existing shareholder, indicating strong market confidence in Lucid's growth potential.
- Underwriter Arrangement: Canaccord Genuity LLC and BTIG, LLC are acting as joint bookrunners for the offering, ensuring professionalism and efficiency in the fundraising process while providing a channel for market outreach.
- Compliance Statement: The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC, ensuring compliance and providing transparent disclosures to investors, thereby reducing potential legal risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAVM
Wall Street analysts forecast PAVM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.140
Low
17.00
Averages
17.00
High
17.00
Current: 7.140
Low
17.00
Averages
17.00
High
17.00
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will outline the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results: CFO Dennis McGrath will discuss PAVmed's first quarter 2026 financial results during the call, expected to provide key financial metrics to assess the company's market performance and financial health.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, allowing investors to dial in through specified numbers, ensuring broad dissemination and transparency of information.
- Replay Accessibility: Following the call, a replay will be available for 30 days on the investor relations section of the company's website, facilitating access for investors who could not participate live, thereby enhancing communication efficiency between the company and its investors.
See More
PAVmed to Host Business Update Conference Call
- Conference Call Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and future growth potential.
- Webcast Availability: The webcast will be available on the investor relations section of the company's website, allowing global investors to participate in real-time and access the latest information, enhancing transparency and engagement.
- Replay Service: A replay of the call will be available for 30 days on the company's website, ensuring that investors who cannot attend live can still access important information, further improving communication efficiency between the company and its investors.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D., will outline the company's operations and growth strategy, which is expected to positively influence investor sentiment.
- Financial Results: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with direct access to information, which is likely to boost investor confidence.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the current healthcare industry's emphasis on early diagnosis.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Call Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations Access: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with convenient access to important information.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the company's long-term social responsibility and market needs.
See More
Lucid Diagnostics Closes $18 Million Share Offering
- Offering Size: Lucid Diagnostics successfully completed an underwritten registered direct offering of 18 million common shares at $1.00 per share, with gross proceeds of approximately $18 million, reflecting market confidence in its cancer prevention technology.
- Investor Backing: The offering was anchored by a $15 million investment from a fundamental institutional investor, along with support from a large existing shareholder, indicating the company's appeal and potential growth prospects in the capital markets.
- Use of Proceeds: The company intends to utilize the net proceeds from this offering for working capital and general corporate purposes, which will aid in its ongoing research and market promotion in the field of early cancer detection.
- Regulatory Compliance: The offering was conducted under a shelf registration statement on Form S-3 declared effective by the SEC on March 26, 2026, ensuring compliance and laying the groundwork for future capital operations.
See More
Lucid Diagnostics Prices $18 Million Direct Offering of Common Shares
- Offering Size: Lucid Diagnostics announced the pricing of 18 million common shares at $1.00 each, expecting gross proceeds of approximately $18 million, which will provide essential funding for working capital and general corporate purposes.
- Investor Backing: The offering is anchored by a $15 million investment from a fundamental institutional investor, along with support from a large existing shareholder, indicating strong market confidence in Lucid's growth potential.
- Underwriter Arrangement: Canaccord Genuity LLC and BTIG, LLC are acting as joint bookrunners for the offering, ensuring professionalism and efficiency in the fundraising process while providing a channel for market outreach.
- Compliance Statement: The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC, ensuring compliance and providing transparent disclosures to investors, thereby reducing potential legal risks.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will outline the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results: CFO Dennis McGrath will discuss PAVmed's first quarter 2026 financial results during the call, expected to provide key financial metrics to assess the company's market performance and financial health.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, allowing investors to dial in through specified numbers, ensuring broad dissemination and transparency of information.
- Replay Accessibility: Following the call, a replay will be available for 30 days on the investor relations section of the company's website, facilitating access for investors who could not participate live, thereby enhancing communication efficiency between the company and its investors.
See More
PAVmed to Host Business Update Conference Call
- Conference Call Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and future growth potential.
- Webcast Availability: The webcast will be available on the investor relations section of the company's website, allowing global investors to participate in real-time and access the latest information, enhancing transparency and engagement.
- Replay Service: A replay of the call will be available for 30 days on the company's website, ensuring that investors who cannot attend live can still access important information, further improving communication efficiency between the company and its investors.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D., will outline the company's operations and growth strategy, which is expected to positively influence investor sentiment.
- Financial Results: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with direct access to information, which is likely to boost investor confidence.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the current healthcare industry's emphasis on early diagnosis.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Call Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations Access: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with convenient access to important information.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the company's long-term social responsibility and market needs.
See More
Lucid Diagnostics Closes $18 Million Share Offering
- Offering Size: Lucid Diagnostics successfully completed an underwritten registered direct offering of 18 million common shares at $1.00 per share, with gross proceeds of approximately $18 million, reflecting market confidence in its cancer prevention technology.
- Investor Backing: The offering was anchored by a $15 million investment from a fundamental institutional investor, along with support from a large existing shareholder, indicating the company's appeal and potential growth prospects in the capital markets.
- Use of Proceeds: The company intends to utilize the net proceeds from this offering for working capital and general corporate purposes, which will aid in its ongoing research and market promotion in the field of early cancer detection.
- Regulatory Compliance: The offering was conducted under a shelf registration statement on Form S-3 declared effective by the SEC on March 26, 2026, ensuring compliance and laying the groundwork for future capital operations.
See More
Lucid Diagnostics Prices $18 Million Direct Offering of Common Shares
- Offering Size: Lucid Diagnostics announced the pricing of 18 million common shares at $1.00 each, expecting gross proceeds of approximately $18 million, which will provide essential funding for working capital and general corporate purposes.
- Investor Backing: The offering is anchored by a $15 million investment from a fundamental institutional investor, along with support from a large existing shareholder, indicating strong market confidence in Lucid's growth potential.
- Underwriter Arrangement: Canaccord Genuity LLC and BTIG, LLC are acting as joint bookrunners for the offering, ensuring professionalism and efficiency in the fundraising process while providing a channel for market outreach.
- Compliance Statement: The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC, ensuring compliance and providing transparent disclosures to investors, thereby reducing potential legal risks.
See More
